Top stories from the Proactive Investors UK newsroom.
Allergy Therapeutics (LON:AGY) has accepted US$7.6mln in settlement of a dispute over the procedures used for a US grass pollen vaccine trial. Allergy blamed the inconclusive trial results on the way the study was carried out.
Graphene specialist Directa Plus (LON:DCTA) has been awarded a patent in the US for its manufacturing process that just uses water with no chemicals. Directa said this sustainability was already proving attractive to US companies.
BlueJay Mining’s (LON:JAY) Dundas minerals sands project in Greenland is worth US$83mln over a nine-year mine life according to a pre-feasibility study. Costs to build the mine and infrastructure are estimated at US$245mln.
Kingfisher has appointed a veteran of French supermarket Carrefour as its new chief executive in the autumn.
Serco’s revenues this year will be at the top end of expectations while orders have also climbed to £3bn. The outsourcer left trading profit guidance unchanged at £105mln.
Boeing’s hopes of getting clearance for its troubled 737 Max aircraft have been dashed again as US regulators have unearthed another problem. The potential risk was discovered during simulator tests.